8-K current report · filed Oct 27, 2026

Nautilus Biotechnology Inc (NAUT) 8-K Current Report: October 27, 2026

Item 2.02Item EX-99.1NAUT overview

Short answer

Nautilus Biotechnology Inc (NAUT) filed an 8-K current report with the SEC on October 27, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Press release announces Nautilus Biotechnology’s Q3 2026 financial results for the quarter ended September 30, 2026.

Nautilus Biotechnology Inc 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Press release announces Nautilus Biotechnology’s Q3 2026 financial results for the quarter ended September 30, 2026
  • Investors should review Exhibit 99.1 for reported financial performance and management commentary

Item EX-99.1 · Exhibit EX-99.1

  • Q3 revenue $0.234M, primarily grants, versus $0 in Q3 2025, signaling an early commercialization stage
  • Operating expenses $16.947M, up 10% year over year, driven by laboratory, professional services, salaries and benefits
  • Net loss $15.636M, versus $13.574M, while nine-month loss reached $44.802M
  • Cash, equivalents and investments $114.3M at September 30, 2026, with nine-month operating cash burn of $40.107M
  • SEEDS consortium could provide up to $6M over four years, but funding remains subject to reduction, delay or termination

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Nautilus Biotechnology Inc 8-K filings

Get the next NAUT 8-K as it lands

Follow NAUT for push alerts, or ask the research agent what this filing means.